Status: Recruiting
Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: First Affiliated Hospital of Zhejiang UniversityUpdated: Feb 4, 2026Locations: 5
Eligibility criteria
Understand the research and sign a written informed consent form; [+9]
Diagnosis of: AML arising from chronic myeloid leukemia (CML); myeloid sarcoma;... [+9]